Communiqués BioNTech SE Wiener Boerse

Actions

BNTX

US09075V1026

Recherche biotechnologique et médicale

Cours en clôture Wiener Boerse 25/09/2026			Varia. 5j.	Varia. 1 janv.
86,65 ^EUR	+0,35%		+3,52%	+6,78%

25/09	Les actions européennes négociées aux États-Unis sous forme de certificats américains de dépôt (ADR) progressent légèrement vendredi, mais reculent sur la semaine	MT
22/09	Un initié de Biontech a vendu des actions pour une valeur de 7 860 757 dollars, selon un récent dépôt auprès de la SEC	MT

Communiqués

17/09	Health Canada Authorizes Pfizer and BioNTech's Omicron XFG-Adapted COVID-19 Vaccine	AQ
14/09	BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients	GL
27/08	Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine	GL
20/08	BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026	GL
04/08	BioNTech : Q2 2026 Finanzbericht	PU
04/08	BioNTech : BNTX Q2 2026 Exhibit 99.1 (Quarterly Report)	PU
04/08	BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update	GL
03/08	BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer	GL
29/07	European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union	GL
22/07	The UPC’s Growing Role In COVID Patent Disputes	AQ
21/07	BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026	GL
24/06	A Sovereign Bet On Science Could Save Millions of Lives	AQ
30/05	Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial	GL
22/05	BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting	GL
18/05	BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026	AQ
15/05	BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026	GL
07/05	BioNTech Announces New ADS Repurchase Program	GL
05/05	BioNTech : BNTX 1Q 2026 Presentation	PU
05/05	BioNTech : Q1 2026 Präsentation	PU
05/05	BioNTech : BNTX Q1 2026 Exhibit 99.1 (Quarterly Report)	PU
05/05	BioNTech : Q1 2026 Finanzbericht	PU
05/05	BioNTech : BNTX 4QFY 2025 Presentation FINAL 200326 v2	PU
05/05	BioNTech Announces First Quarter 2026 Financial Results and Corporate Update	GL
21/04	BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026	GL
13/04	BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer	AQ